Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Personalis Net Common Equity Issued/Repurchased 2018-2025 | PSNL

Personalis net common equity issued/repurchased from 2018 to 2025. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
  
Personalis Annual Net Common Equity Issued/Repurchased
(Millions of US $)
2024 $117
2023 $11
2022 $N/A
2021 $162
2020 $118
2019 $144
2018 $N/A
2017 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.417B $0.085B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $18.765B 6.78
Dr Reddy's Laboratories (RDY) India $11.962B 21.71
BridgeBio Pharma (BBIO) United States $6.236B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.827B 14.83
Bausch Health Cos (BHC) Canada $1.623B 1.19
Amphastar Pharmaceuticals (AMPH) United States $1.148B 7.65
Taysha Gene Therapies (TSHA) United States $0.620B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.022B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00